IJCM  Vol.4 No.8 , August 2013
A Minimally Invasive Surgery for Bone Metastases Using the Combination of Photodynamic Therapy and Hyperthermia Treatment
ABSTRACT

Cancer patients with bone metastases in their extremities may require surgical intervention to prevent deterioration in their quality of life due to a pathological fracture or severe bone pain. However, curative surgical interventions sometimes have severe complications due to the status of the original cancers. To avoid the decreased quality of life caused by bone metastasis, minimally invasive surgery that avoids additional surgical morbidity is required. We have established two therapeutic treatments for bone metastasis, a photodynamic acridine orange treatment (AOT) and an electronic magnetic hyperthermia treatment (EMHT). The present study investigated the clinical outcomes of combination therapy with EMHT and AOT for patients with bone metastases in their extremities. Methods: The study included 6 patients with 7 bone cancer metastasis locations. For bone metastases, all patients received intraregional tumor excision supported by AOT, in which photodynamic and radiodynamic therapy kills tumor cells during surgery with minimal damage to normal tissues. After the curettage, bone reconstruction was performed by using magnetic materials with calcium phosphate cement. EMHT was repeatedly performed after surgery. In EMHT, tumor cells are killed with an electric magnetic field generator, and bony union is promoted by electronic stimulation. Results: The mean duration of follow-up was 14 months. During the follow-up period, only one patient experienced a local recurrence, and this recurrence occurred 14 months after surgery. Bony union occurred in 4 of 5 cases (80%), and the pain score was significantly reduced after surgery. Conclusions: In the present study, AOT reduced the invasiveness of surgery. EMHT reduced the tumor growth without major complications and promoted bone formation after surgery. Our clinical results confirmed that EMHT and AOT combination therapy for bone metastasis can preserve limb function without local recurrence or bone absorption.


Cite this paper
T. Matsubara, A. Matsumine, K. Kusuzaki, K. Asanuma, T. Nakamura, A. Uchida and A. Sudo, "A Minimally Invasive Surgery for Bone Metastases Using the Combination of Photodynamic Therapy and Hyperthermia Treatment," International Journal of Clinical Medicine, Vol. 4 No. 8, 2013, pp. 357-363. doi: 10.4236/ijcm.2013.48064.
References
[1]   P. Bohm and J. Huber, “The Surgical Treatment of Bony Metastases of the Spine and Limbs,” The Journal of Bone and Joint Surgery. British Volume, Vol. 84, No. 4, 2002, pp. 521-529. doi:10.1302/0301-620X.84B4.12495

[2]   R. E. Coleman, “Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity,” Clinical Cancer Research, Vol. 12, No. 20, 2006, pp. 6243s-6249s. doi:10.1158/1078-0432.CCR-06-0931

[3]   D. J. Jacofsky, P. J. Papagelopoulos and F. H. Sim, “Advances and Challenges in the Surgical Treatment of Metastatic Bone Disease,” Clinical Orthopaedics and Related Research, No. 415, 2003, pp. S14-S18.

[4]   O. Ofluoglu, B. Erol, Z. Ozgen and M. Yildiz, “Minimally Invasive Treatment of Pathological Fractures of the Humeral Shaft,” International Orthopaedics, Vol. 33, No. 3, 2009, pp. 707-712. doi:10.1007/s00264-008-0540-0

[5]   C. M. Ogilvie, E. J. Fox and R. D. Lackman, “Current Surgical Management of Bone Metastases in the Extremities and Pelvis,” Seminars in Oncology, Vol. 35, No. 2, 2008, pp. 118-128. doi:10.1053/j.seminoncol.2007.11.019

[6]   S. Utzschneider, E. Wicherek, P. Weber, G. Schmidt, V. Jansson and H. R. Durr, “Surgical Treatment of Bone Metastases in Patients with Lung Cancer,” International Orthopaedics, Vol. 35, No. 5, 2011, pp. 731-736. doi:10.1007/s00264-010-1074-9

[7]   J. S. Keene, D. S. Sellinger, A. A. McBeath and W. D. Engber, “Metastatic Breast Cancer in the Femur. A Search for the Lesion at Risk of Fracture,” Clinical Orthopaedics and Related Research, No. 203, 1986, pp. 282-288.

[8]   Y. M. Van der Linden, P. D. Dijkstra, H. M. Kroon, J. J. Lok, E. M. Noordijk, J. W. Leer and C. A. Marijnen, “Comparative Analysis of Risk Factors for Pathological Fracture with Femoral Metastases,” The Journal of Bone and Joint Surgery. British Volume, Vol. 86, No. 4, 2004, pp. 566-573.

[9]   K. Kusuzaki, S. Hosogi, E. Ashihara, T. Matsubara, H. Satonaka, T. Nakamura, A. Matsumine, A. Sudo, A. Uchida, H. Murata, N. Baldini, S. Fais and Y. Marunaka, “Translational Research of Photodynamic Therapy with Acridine Orange Which Targets Cancer Acidity,” Current Pharmaceutical Design, Vol. 18, No. 10, 2012, pp. 1414-1420. doi:10.2174/138161212799504812

[10]   K. Kusuzaki, H. Murata, T. Matsubara, S. Miyazaki, A. Okamura, M. Seto, A. Matsumine, H. Hosoi, T. Sugimoto and A. Uchida, “Clinical Trial of Photodynamic Therapy Using Acridine Orange with/without Low Dose Radiation as New Limb Salvage Modality in Musculoskeletal Sarcomas,” Anticancer Research, Vol. 25, No. 2B, 2005, pp. 1225-1235.

[11]   K. Kusuzaki, H. Murata, T. Matsubara, S. Miyazaki, K. Shintani, M. Seto, A. Matsumine, H. Hosoi, T. Sugimoto and A. Uchida, “Clinical Outcome of a Novel Photodynamic Therapy Technique Using Acridine Orange for Synovial Sarcomas,” Photochemistry and Photobiology, Vol. 81, No. 3, 2005, pp. 705-709. doi:10.1562/2004-06-27-RA-218

[12]   K. Kusuzaki, H. Murata, T. Matsubara, H. Satonaka, T. Wakabayashi, A. Matsumine and A. Uchida, “Review. Acridine Orange Could Be an Innovative Anticancer Agent under Photon Energy,” In Vivo (Athens, Greece), Vol. 21, No. 2, 2007, pp. 205-214.

[13]   T. Matsubara, K. Kusuzaki, A. Matsumine, H. Murata, T. Nakamura, A. Uchida and A. Sudo, “Clinical Outcomes of Minimally Invasive Surgery Using Acridine Orange for Musculoskeletal Sarcomas around the Forearm, Compared with Conventional Limb Salvage Surgery after Wide Resection,” Journal of Surgical Oncology, Vol. 102, No. 3, 2010, pp. 271-275. doi:10.1002/jso.21602

[14]   T. Matsubara, K. Kusuzaki, A. Matsumine, H. Murata, H. Satonaka, K. Shintani, T. Nakamura, H. Hosoi, T. Iehara, T. Sugimoto and A. Uchida, “A New Therapeutic Modality Involving Acridine Orange Excitation by Photon Energy Used during Reduction Surgery for Rhabdomyosarcomas,” Oncology Reports, Vol. 21, No. 1, 2009, pp. 89-94.

[15]   T. Matsubara, K. Kusuzaki, A. Matsumine, T. Nakamura and A. Sudo, “Can a Less Radical Surgery Using Photodynamic Therapy With Acridine Orange Be Equal to a Wide-Margin Resection?” Clinical Orthopaedics and Related Research, Vol. 471, No. 3, 2013, pp. 792-802. doi:10.1007/s11999-012-2616-9

[16]   T. Nakamura, K. Kusuzaki, T. Matsubara, A. Matsumine, H. Murata and A. Uchida, “A New Limb Salvage Surgery in Cases of High-Grade Soft Tissue Sarcoma Using Photodynamic Surgery, Followed by Photo- and Radio-dynamic Therapy with Acridine Orange,” Journal of Surgical Oncology, Vol. 97, No. 6, 2008, pp. 523-528. doi:10.1002/jso.21025

[17]   K. Yoshida, K. Kusuzaki, T. Matsubara, A. Matsumine, T. Kumamoto, Y. Komada, N. Naka and A. Uchida, “Periosteal Ewing’s Sarcoma Treated by Photodynamic Therapy with Acridine Orange,” Oncology Reports, Vol. 13, No. 2, 2005, pp. 279-282.

[18]   K. Kusuzaki, K. Aomori, T. Suginoshita, G. Minami, H. Takeshita, H. Murata, S. Hashiguchi, T. Ashihara and Y. Hirasawa, “Total Tumor Cell Elimination with Minimum Damage to Normal Tissues in Musculoskeletal Sarcomas Following Photodynamic Therapy with Acridine Orange,” Oncology, Vol. 59, No. 2, 2000, pp. 174-180.

[19]   K. Kusuzaki, G. Minami, H. Takeshita, H. Murata, S. Hashiguchi, T. Nozaki, T. Ashihara and Y. Hirasawa, “Photodynamic Inactivation with Acridine Orange on a Multidrug-Resistant Mouse Osteosarcoma Cell Line,” Japanese Journal of Cancer Research, Vol. 91, No. 4, 2000, pp. 439-445. doi:10.1111/j.1349-7006.2000.tb00964.x

[20]   K. Kusuzaki, H. Murata, H. Takeshita, S. Hashiguchi, T. Nozaki, K. Emoto, T. Ashihara and Y. Hirasawa, “Intracellular Binding Sites of Acridine Orange in Living Osteosarcoma Cells,” Anticancer Research, Vol. 20, No. 2A, 2000, pp. 971-975.

[21]   K. Kusuzaki, T. Suginoshita, G. Minami, K. Aomori, H. Takeshita, H. Murata, S. Hashiguchi, T. Ashihara and Y. Hirasawa, “Fluorovisualization Effect of Acridine Orange on Mouse Osteosarcoma,” Anticancer Research, Vol. 20, No. 5A, 2000, pp. 3019-3024.

[22]   S. Hashiguchi, K. Kusuzaki, H. Murata, H. Takeshita, M. Hashiba, T. Nishimura, T. Ashihara and Y. Hirasawa, “Acridine Orange Excited by Low-Dose Radiation Has a Strong Cytocidal Effect on Mouse Osteosarcoma,” Oncology, Vol. 62, No. 1, 2002, pp. 85-93. doi:10.1159/000048251

[23]   A. Matsumine, K. Kusuzaki, T. Matsubara, K. Shintani, H. Satonaka, T. Wakabayashi, S. Miyazaki, K. Morita, K. Takegami and A. Uchida, “Novel Hyperthermia for Metastatic Bone Tumors with Magnetic Materials by Generating an Alternating Electromagnetic Field,” Clinical & Experimental Metastasis, Vol. 24, No. 3, 2007, pp. 191-200. doi:10.1007/s10585-007-9068-8

[24]   A. Matsumine, K. Takegami, K. Asanuma, T. Matsubara, T. Nakamura, A. Uchida and A. Sudo, “A Novel Hyperthermia Treatment for Bone Metastases Using Magnetic Materials,” International Journal of Clinical Oncology, Vol. 16, No. 2, 2011, pp. 101-108. doi:10.1007/s10147-011-0217-3

[25]   H. Ueda, H. Murata, H. Takeshita, G. Minami, S. Hashiguchi and T. Kubo, “Unfiltered Xenon Light Is Useful for Photodynamic Therapy with Acridine Orange,” Anticancer Research, Vol. 25, No. 6B, 2005, pp. 3979-3983.

[26]   H. Katagiri, M. Takahashi, K. Wakai, H. Sugiura, T. Kataoka and K. Nakanishi, “Prognostic Factors and a Scoring System for Patients with Skeletal Metastasis,” The Journal of Bone and Joint Surgery. British Volume, Vol. 87, No. 5, 2005, pp. 698-703. doi:10.1302/0301-620X.87B5.15185

[27]   A. Piccioli, A. Ventura, G. Maccauro, M. S. Spinelli, V. Del Bravo and M. A. Rosa, “Local Adjuvants in Surgical Management of Bone Metastases,” International Journal of Immunopathology and Pharmacology, Vol. 24, No. 1, 2011, pp. 129-132.

[28]   T. Matsubara, K. Kusuzaki, A. Matsumine, K. Shintani, H. Satonaka and A. Uchida, “Acridine Orange Used for Photodynamic Therapy Accumulates in Malignant Musculoskeletal Tumors Depending on pH Gradient,” Anticancer Research, Vol. 26, No. 1A, 2006, pp. 187-193.

[29]   F. J. Frassica and D. A. Frassica, “Evaluation and Treatment of Metastases to the Humerus,” Clinical Orthopaedics and Related Research, No. 415, 2003, pp. S212-S218. doi:10.1097/01.blo.0000093052.96273.a7

[30]   S. Adie, I. A. Harris, J. M. Naylor, H. Rae, A. Dao, S. Yong and V. Ying, “Pulsed Electromagnetic Field Stimulation for Acute Tibial Shaft Fractures: A Multicenter, Double-Blind, Randomized Trial,” The Journal of Bone and Joint Surgery, American Volume, Vol. 93, No. 17, 2011, pp. 1569-1576. doi:10.2106/JBJS.J.00869

[31]   X. L. Griffin, M. L. Costa, N. Parsons and N. Smith, “Electromagnetic Field Stimulation for Treating Delayed Union or Non-Union of Long Bone Fractures in Adults,” Cochrane Database of Systematic Reviews (Online), No. 4, 2011, Article ID: CD008471. doi:10.1002/14651858.CD008471.pub2

[32]   P. Hannemann, K. W. Gottgens, B. J. van Wely, K. A. Kolkman, A. J. Werre, M. Poeze and P. R. Brink, “Pulsed Electromagnetic Fields in the Treatment of Fresh Scaphoid Fractures. A Multicenter, Prospective, Double Blind, Placebo Controlled, Randomized Trial,” BMC Musculos-keletal Disorders, Vol. 12, 2011, p. 90. doi:10.1186/1471-2474-12-90

[33]   H. F. Shi, J. Xiong, Y. X. Chen, J. F. Wang, X. S. Qiu, Y. H. Wang and Y. Qiu, “Early Application of Pulsed Electromagnetic Field in the Treatment of Postoperative Delayed Union of Long-Bone Fractures: A Prospective Randomized Controlled Study,” BMC Musculoskeletal Disorders, Vol. 14, 2013, p. 35. doi:10.1186/1471-2474-14-35

[34]   S. Adachi, S. Kokura, T. Okayama, T. Ishikawa, T. Takagi, O. Handa, Y. Naito and T. Yoshikawa, “Effect of Hyperthermia Combined with Gemcitabine on Apoptotic Cell Death in Cultured Human Pancreatic Cancer Cell Lines,” International Journal of Hyperthermia, Vol. 25, No. 3, 2009, pp. 210-219. doi:10.1080/02656730802657036

[35]   T. Ishikawa, S. Kokura, N. Sakamoto, T. Ando, E. Imamoto, T. Hattori, H. Oyamada, N. Yoshinami, M. Sakamoto, K. Kitagawa, Y. Okumura, N. Yoshida, K. Kamada, K. Katada, K. Uchiyama, O. Handa, T. Takagi, H. Yasuda, J. Sakagami, H. Konishi, N. Yagi, Y. Naito and T. Yoshikawa, “Phase II Trial of Combined Regional Hyperthermia and Gemcitabine for Locally Advanced or Metastatic Pancreatic Cancer,” International Journal of Hyperthermia, Vol. 28, No. 7, 2012, pp. 597-604. doi:10.3109/02656736.2012.695428

[36]   T. Okayama, S. Kokura, T. Ishikawa, S. Adachi, T. Hattori, T. Takagi, O. Handa, Y. Naito and T. Yoshikawa, “Antitumor Effect of Pretreatment for Colon Cancer Cells with Hyperthermia Plus Geranylgeranylacetone in Experimental Metastasis Models and a Subcutaneous Tumor Model of Colon Cancer in Mice,” International Journal of Hyperthermia, Vol. 25, No. 2, 2009, pp. 141-149. doi:10.1080/02656730802631783

 
 
Top